Refine
Has Fulltext
- yes (58)
Is part of the Bibliography
- yes (58)
Year of publication
Document Type
- Journal article (44)
- Conference Proceeding (8)
- Preprint (6)
Keywords
- PET (23)
- Positronen-Emissions-Tomografie (20)
- positron emission tomography (12)
- theranostics (10)
- PRRT (8)
- neuroendocrine tumor (8)
- SSTR (6)
- CXCR4 (5)
- PET/CT (5)
- RADS (5)
- SPECT (5)
- prostate cancer (5)
- 18F-FDG (4)
- PSMA (4)
- somatostatin receptor (4)
- 18F-DCFPyL (3)
- 18F-LMI1195 (3)
- DaTscan (3)
- NET (3)
- Prostate Cancer (3)
- ageing (3)
- molecular imaging (3)
- peptide receptor radionuclide therapy (3)
- prostate-specific membrane antigen (3)
- sympathetic nervous system (3)
- vandetanib (3)
- 11C-HED (2)
- 18F-FDS (2)
- DOTATOC (2)
- ECG (2)
- Ioflupane (2)
- MAG3 (2)
- Neuroendocrine Tumor (2)
- PSMA-PET (2)
- PSMA-RADS (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Positron Emission Tomography (2)
- SSTR-RADS (2)
- Stammzelle (2)
- TKI (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- cardiomyocytes (2)
- chemokine receptor (2)
- diabetes (2)
- fatty acid (2)
- heart failure (2)
- hiPSC-CM (2)
- induced pluripotent stem cells (2)
- kidney (2)
- medullary thyroid carcinoma (2)
- molecular medicine (2)
- myocardial sympathetic innervation imaging (2)
- norepinephrine transporter (2)
- personalized medicine (2)
- personalized treatment (2)
- precision medicine (2)
- radioligand therapy (2)
- reporting and data system (2)
- stem cell therapy (2)
- tracer (2)
- tumor heterogeneity (2)
- tyrosine kinase inhibitor (2)
- 11C-Hydroxyephedrine (1)
- 11C-hydroxyephedrine (1)
- 123I-Ioflupane (1)
- 123I-mIBG (1)
- 123I-metaiodobenzylguanidine (1)
- 177Lu (1)
- 177Lu-DOTATATE (1)
- 177Lu-DOTATOC (1)
- 18F-DCFPL (1)
- 18F-flurpiridaz (1)
- 18FFBnTP (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-DOTATOC (1)
- 99mTc-DTPA (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- Antidepressants (1)
- Arginine (1)
- C-X-C motif chemokine receptor 4 (1)
- Cardiovascular diseases (1)
- Diabetes (1)
- ECG-gated (1)
- EKG (1)
- GI (1)
- Ganglia (1)
- Gastrointestinal (1)
- Glomerular filtration (1)
- HFmrEF (1)
- Heart failure (1)
- Herz (1)
- Hyperkalaemia (1)
- Imaging pitfalls (1)
- Lysine (1)
- MDD (1)
- MI-RADS (1)
- MIBG (1)
- MPI (1)
- MRI (1)
- Medullärer Schilddrüsenkrebs (1)
- Metaiodobenzylguanidine (1)
- Myocardial-perfusion SPECT (1)
- Myokarditis (1)
- NEC (1)
- Neuroendocrine (1)
- Nierenfunktionsstörung (1)
- Oncology (1)
- PROMISE (1)
- PSMA-RADS-3A (1)
- PSMA-RADS-3B (1)
- PSMA-targeted PET (1)
- Pancreas (1)
- Parkinsonism (1)
- Parkinson’s disease (1)
- Pitfall (1)
- Positron-Emission Tomography (1)
- Positronenemissionstomografie (1)
- Prostata (1)
- Radiofluorine (1)
- Radionuclide Therapy (1)
- Radiotracer (1)
- SPECT Scanner (1)
- SPECT/CT (1)
- SSTR-PET (1)
- SUV (1)
- Single-Photon-Emissions-Computertomographie (1)
- Sodium-Glucose Cotransporters (SGLTs) (1)
- Standardisierung (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- Tracer (1)
- ZDF rats (1)
- [177Lu]/[90Y]PentixaTher (1)
- [68Ga]DOTATOC (1)
- [68Ga]PentixaFor (1)
- [68Ga]Pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{18}\)F (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- \(^{68}\)Ga (1)
- amino acids (1)
- angiogenesis (1)
- antidepressant (1)
- antidepressants (1)
- autonomic nervous system (1)
- biomarkers (1)
- cardiac (1)
- cardiac innervation imaging (1)
- cardiac neurohormonal system (1)
- cardiac sympathetic nerve system (1)
- cardiac sympathetic nervous system (1)
- coronary artery disease (1)
- depression (1)
- diabetic cardiomyopathy (1)
- diabetische Kardiomyopathie (1)
- ejection fraction (1)
- endocrinology (1)
- endoradiotherapy (1)
- fibroblast activation protein (1)
- glomerular filtration rate (1)
- heart (1)
- heart failure with mid-range ejection fraction (1)
- hydroxyephedrine (1)
- hyperkalemia (1)
- immune infiltration (1)
- inflammation (1)
- interobserver (1)
- interreader (1)
- kidney function (1)
- left-ventricular function (1)
- mIBG (1)
- mRNA (1)
- machine learning (1)
- major depressive disorder (1)
- medicine (1)
- medium-sized animals (1)
- miRNA (1)
- moycardial sympathetic innervation (1)
- multiple myeloma (1)
- myocardial perfusion imaging (1)
- myocarditis (1)
- nephrology (1)
- neuroendocrine neoplasia (1)
- nonhuman primates (1)
- nuclear cardiology (1)
- pancreas (1)
- performance (1)
- phaeochromocytoma (1)
- prostate-specific membrane antigen (PSMA) (1)
- quantification (1)
- radiotracer (1)
- radiotracer kinetics (1)
- rats (1)
- renal (1)
- renal failure (1)
- renal function (1)
- renal imaging (1)
- renal scintigraphy (1)
- reporting and data systems (1)
- sarcoidosis (1)
- single photon emission computed tomography: sympathetic nerve (1)
- solid tumors (1)
- somatostatin receptor (SSTR) (1)
- split renal function (1)
- standardization (1)
- standardized reporting (1)
- stem cells (1)
- stem-cell research (1)
- storage vesicle turnover (1)
- structure–activity relationships (1)
- sympathetic nerve (1)
- transcriptome (1)
- tumor microenvironment (1)
- unilateral ureteral obstruction (1)
- urology (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (58)
- Medizinische Klinik und Poliklinik I (9)
- Medizinische Klinik und Poliklinik II (9)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (6)
- Institut für Anatomie und Zellbiologie (3)
- Institut für Pharmazie und Lebensmittelchemie (3)
- Pathologisches Institut (3)
- Comprehensive Cancer Center Mainfranken (2)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (16)
- Johns Hopkins University School of Medicine (5)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (3)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (2)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (2)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (2)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (2)
- Department of Nuclear Medicine, Kanazawa University (1)
- Hospital Augsburg, Augsburg, Germany (1)
- Johns Hopkins School of Medicine, Baltimore, MD, USA (1)
EU-Project number / Contract (GA) number
- 701983 (35)
C-X-C-motif chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. We have recently reported promising first-in-man experience with CXCR4-directed endoradiotherapy (ERT) in multiple myeloma (MM).
Eight heavily pretreated MM patients underwent a total of 10 ERT cycles (7 patients with 1 cycle and a single patient with 3 cycles). ERT was administered in combination with chemotherapy and autologous stem cell support. End points were occurrence and timing of adverse events, progression-free and overall survival.
ERT was overall well tolerated without any unexpected acute adverse events or changes in vital signs. With absorbed tumor doses >30-70 Gy in intra- or extramedullary lesions, significant anti-myeloma activity was observed with 1 patient achieving complete remission and 5/8 partial remission. Directly after ERT major infectious complications were seen in one patient who died from sepsis 22 days after ERT, another patient with high tumor burden experienced lethal tumor lysis syndrome. Median progression-free survival was 54 days (range, 13-175), median overall survival was 223 days (range, 13-313). During follow-up (6 patients available), one patient died from infectious complications, 2/8 from disease progression, the remaining 3/8 patients are still alive.
CXCR4-directed ERT was well-tolerated and exerted anti-myeloma activity even at very advanced stage MM with presence of extramedullary disease. Further assessment of this novel treatment option is highly warranted.